PMID- 34124820 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20221213 IS - 1098-2264 (Electronic) IS - 1045-2257 (Print) IS - 1045-2257 (Linking) VI - 60 IP - 10 DP - 2021 Oct TI - Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. PG - 678-686 LID - 10.1002/gcc.22977 [doi] AB - Plasma cell neoplasms (PCN) and mantle cell lymphoma (MCL) can both harbor t(11;14)(q13;q32) (CCND1/IGH), usually resulting in cyclin D1 overexpression. In some cases, particularly at low levels of disease, it can be morphologically challenging to distinguish between these entities in the bone marrow (BM) since PCN with t(11;14) are often CD20-positive with lymphoplasmacytic cytology, while MCL can rarely have plasmacytic differentiation. We compared the difference in CCND1/IGH by fluorescence in situ hybridization (FISH) in PCN and MCL to evaluate for possible differentiating characteristics. We identified 326 cases of MCL with t(11;14) and 279 cases of PCN with t(11;14) from either formalin-fixed, paraffin-embedded tissue or fresh BM specimens. The "typical," balanced CCND1/IGH FISH signal pattern was defined as three total CCND1 signals, three total IGH signals, and two total fusion signals. Any deviation from the "typical" pattern was defined as an "atypical" pattern, which was further stratified into "gain of fusion" vs "complex" patterns. There was a significantly higher proportion of cases that showed an atypical FISH pattern in PCN compared with MCL (53% vs 27%, P < .0001). There was also a significantly higher proportion of cases that showed a complex FISH pattern in PCN compared with MCL (47% vs 17%, P < .0001). We confirmed these findings using mate-pair sequencing of 25 PCN and MCL samples. PCN more often have a complex CCND1/IGH FISH pattern compared with MCL, suggesting possible differences in the genomic mechanisms underlying these rearrangements in plasma cells compared with B cells. CI - (c) 2021 The Authors. Genes, Chromosomes and Cancer published by Wiley Periodicals LLC. FAU - Dalland, Joanna C AU - Dalland JC AD - Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Smadbeck, James B AU - Smadbeck JB AUID- ORCID: 0000-0002-8902-0950 AD - Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. FAU - Sharma, Neeraj AU - Sharma N AD - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Meyer, Reid G AU - Meyer RG AD - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Pearce, Kathryn E AU - Pearce KE AD - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Greipp, Patricia T AU - Greipp PT AD - Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. AD - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Peterson, Jess F AU - Peterson JF AUID- ORCID: 0000-0003-2496-8000 AD - Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. AD - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Kumar, Shaji AU - Kumar S AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Ketterling, Rhett P AU - Ketterling RP AD - Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. AD - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - King, Rebecca L AU - King RL AD - Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Baughn, Linda B AU - Baughn LB AUID- ORCID: 0000-0001-5229-4897 AD - Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. AD - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. LA - eng GR - P30 CA015083/CA/NCI NIH HHS/United States GR - P50 CA186781/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210622 PL - United States TA - Genes Chromosomes Cancer JT - Genes, chromosomes & cancer JID - 9007329 SB - IM MH - Chromosomes, Human, Pair 11/*genetics MH - Chromosomes, Human, Pair 14/*genetics MH - *Gene Rearrangement MH - Humans MH - In Situ Hybridization, Fluorescence MH - Lymphoma, Mantle-Cell/genetics/*pathology MH - Neoplasms, Plasma Cell/genetics/*pathology MH - *Translocation, Genetic PMC - PMC8453742 OTO - NOTNLM OT - CCND1 OT - IGH OT - fluorescence in situ hybridization OT - mantle cell lymphoma OT - mate-pair sequencing OT - next-generation sequencing OT - plasma cell neoplasms OT - t(11;14)(q13;q32) COIS- Shaji Kumar served as a consultant for Celgene, Takeda, Amgen, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Takeda, Novartis, Amgen, AbbVie, Janssen, and Bristol-Myers Squibb. The remaining authors declare no competing financial interests. EDAT- 2021/06/15 06:00 MHDA- 2022/03/08 06:00 PMCR- 2021/09/21 CRDT- 2021/06/14 10:05 PHST- 2021/06/03 00:00 [revised] PHST- 2021/02/11 00:00 [received] PHST- 2021/06/04 00:00 [accepted] PHST- 2021/06/15 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/06/14 10:05 [entrez] PHST- 2021/09/21 00:00 [pmc-release] AID - GCC22977 [pii] AID - 10.1002/gcc.22977 [doi] PST - ppublish SO - Genes Chromosomes Cancer. 2021 Oct;60(10):678-686. doi: 10.1002/gcc.22977. Epub 2021 Jun 22.